Correspondence
Further considerations on the FINEARTS-HF trial
First published: 12 May 2025
No abstract is available for this article.
References
- 1Butt JH, Jhund PS, Henderson AD, Claggett BL, Desai AS, Lam CSP, Brinker M, Schloemer P, Viswanathan P, Lage A, Rohwedder K, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray J Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial. Eur J Heart Fail, https://doi.org/10.1002/ejhf.3649. Published online ahead of print 10/04/25.
- 2 American Diabetes Association Professional Practice Committee. 2. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2022. Diabetes Care 2022; 45: S17–S38. https://doi.org/10.2337/dc22-S002
- 3Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al.; FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020; 383(23): 2219–2229. https://doi.org/10.1056/NEJMoa2025845
- 4Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al.; FIGARO-DKD Investigators. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 2021; 385(24): 2252–2263. https://doi.org/10.1056/NEJMoa2110956
- 5McMurray JJV Solomon SD Inzucchi SE Køber L Kosiborod MN Martinez FA, et al.; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction N Engl J Med 2019 381 1995 2008 https://doi.org/10.1056/NEJMoa1911303
